These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

546 related items for PubMed ID: 17211843

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Von Willebrand factor multimers in virus-inactivated plasmas and F VIII concentrates.
    Budde U, Drewke E.
    Beitr Infusionsther Transfusionsmed; 1994; 32():408-14. PubMed ID: 9422121
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo.
    Shi Q, Kuether EL, Schroeder JA, Perry CL, Fahs SA, Cox Gill J, Montgomery RR.
    J Thromb Haemost; 2012 Nov; 10(11):2328-37. PubMed ID: 22908929
    [Abstract] [Full Text] [Related]

  • 29. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
    Delignat S, Dasgupta S, André S, Navarrete AM, Kaveri SV, Bayry J, André MH, Chtourou S, Tellier Z, Lacroix-Desmazes S.
    Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
    [Abstract] [Full Text] [Related]

  • 30. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA, Saint-Remy JM, Jacquemin M, Benhida A, DiMichele DM.
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
    Sawecka J, Skulimowska J, Windyga J, Lopaciuk S, Kościelak J.
    Arch Immunol Ther Exp (Warsz); 2005 Mar; 53(4):352-6. PubMed ID: 16088320
    [Abstract] [Full Text] [Related]

  • 33. Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?
    Pouplard C, Desconclois C, Sobas F, Aillaud MF, Ternisien C, Caron C.
    Int J Lab Hematol; 2015 Feb; 37(1):125-32. PubMed ID: 24815078
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A.
    Delignat S, Repessé Y, Navarrete AM, Meslier Y, Gupta N, Christophe OD, Kaveri SV, Lacroix-Desmazes S.
    Haemophilia; 2012 Mar; 18(2):248-54. PubMed ID: 22044692
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.